To determine whether the optical coherence tomography location of a subfoveal fibrovascular scar is correlated with visual outcome in eyes successfully treated with antivascular endothelial growth factor agents for neovascular age-related macular degeneration.
Fifty-six eyes from 56 patients with a subfoveal disciform scar after antivascular endothelial growth factor treatment were included. The initial and final visual acuity, fluorescein angiography, and spectral domain optical coherence tomography scar characteristics were retrospectively reviewed.
Thirty-five of 56 eyes (62.5%) were classified as having entirely subretinal pigment epithelial (sub-RPE) scars, and 21 eyes (37.5%) had subretinal component scars. Mean initial visual acuity was similar between sub-RPE and subretinal scars (20/100 vs. 20/125, P = 0.517); mean final visual acuity was better in the sub-RPE scar group (20/60 vs. 20/200, P = 0.001). Eyes with sub-RPE scar had better preservation of the external limiting membrane, ellipsoid layer, and retinal thickness (P < 0.001, P = 0.017, P = 0.004, respectively) than subretinal component scar eyes. There was no difference between the groups in scar thickness or scar area (P = 0.707, P = 0.186, respectively).
Sub-RPE location of subfoveal scarring in eyes treated for neovascular age-related macular degeneration is associated with better preservation of outer retinal structures and better vision, when compared with a subretinal scar.
Subretinal pigment epithelial location of subfoveal scarring in eyes treated for neovascular age-related macular degeneration is associated with better vision and preservation of outer retinal structures, when compared with a subretinal scar.
*Department of Ophthalmology, McGill University, Montreal, Quebec, Canada; and
†Scientific Affairs, JSS Medical Research, Montreal, Quebec, Canada.
Reprint requests: John C. Chen, MD, Department of Ophthalmology, McGill University, 4120 Rue Sainte-Catherine Ouest, Suite 200, Westmount, QC H3Z1P4, Canada; e-mail: firstname.lastname@example.org
Supported in part by an educational grant from Bayer, Canada.
Presented in poster form at the Association for Research in Vision and Ophthalmology Annual Meeting, Orlando, FL, May 6, 2014, and at the World Ophthalmology Congress Annual Meeting, Tokyo, Japan, April 4, 2014.
None of the authors have any financial/conflicting interests to disclose.